Coenzyme Q10 for Hypertension

Verdict: Published with Warning

Across 5 PubMed studies, the evidence for Coenzyme Q10 in Hypertension grades Tier C — weak evidence. Effective, but with safety or population caveats.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.46

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

C · Published with Warning

Confidence

82%

Highly consistent evidence

Evidence level

Cochrane high-quality SR/MA

How strongly each layer supports this effect

lower = less supportive

L5 Clinical bodiesAuthoritative stance

0.43

L2 PubMedPrimary literature

0.45

L3 MechanismPlausibility

0.45

L1 ExamineGlobal benchmark

0.50

L11 AI re-checkIndependent read

0.50

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.456
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高階證據未達主導 (1 positive vs 1 negative)，由 raw_score 決定
tier_strict_requirement_check — Tier 條件達標，未降階
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension

PMID: 26935713 2016 Cochrane Review n = 50

Finding: Across only 2 poolable RCTs (50 participants), CoQ10 did not significantly change systolic BP (MD -3.68 mmHg, 95% CI -8.86 to 1.49) or diastolic BP (MD -2.03 mmHg, 95% CI -4.86 to 0.81), with moderate-quality evidence of no clinically significant effect.

🟢 High quality Government Effect size: SBP MD -3.68 mmHg (95% CI -8.86 to 1.49, NS); DBP MD -2.03 mmHg (95% CI -4.86 to 0.81, NS)

View on PubMed

Dose-Response Effect of Coenzyme Q10 Supplementation on Blood Pressure among Patients with Cardiometabolic Disorders: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials

PMID: 36130103 2022 統合分析 n = 1,831

Finding: Pooling 26 RCTs (1831 subjects with cardiometabolic disease), CoQ10 significantly lowered systolic BP by -4.77 mmHg (95% CI -6.57 to -2.97) with a U-shaped optimum at 100-200 mg/d (moderate-quality evidence), while the diastolic BP effect was only low-quality.

Academic Effect size: SBP WMD -4.77 mmHg (95% CI -6.57 to -2.97); optimal dose 100-200 mg/d (Pnonlinearity=0.004)

View on PubMed

Effects of coenzyme Q10 administration on blood pressure and heart rate in adults: A systematic review and meta-analysis of randomized controlled trials

PMID: 40495903 2025 統合分析

Finding: Across 45 RCTs (48 effect sizes), CoQ10 produced a small but significant systolic BP reduction (WMD -3.44 mmHg, 95% CI -5.13 to -1.55, p<0.01) but no significant effect on diastolic BP (WMD -1.13 mmHg, p=0.23) or heart rate (p=0.44).

Effect size: SBP WMD -3.44 mmHg (95% CI -5.13 to -1.55, p<0.01); DBP WMD -1.13 mmHg (NS, p=0.23); HR NS

View on PubMed

Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials

PMID: 17287847 2007 統合分析 n = 362

Finding: This early meta-analysis of 12 trials (362 patients, mostly open-label/uncontrolled) reported large reductions of up to -17 mmHg systolic and -10 mmHg diastolic, but the effect rested largely on non-randomized data and was not reproduced by the later Cochrane review restricted to RCTs.

🟠 Limited quality Academic Effect size: RCT subset (n=120): SBP -16.6 mmHg (12.6-20.6, P<0.001), DBP -8.2 mmHg (6.2-10.2, P<0.001); open-label SBP -13.5 mmHg

View on PubMed

Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension

PMID: 11780680 2001 RCT (double-blind) n = 83

Finding: In 83 patients, the CoQ10 group showed a mean systolic BP reduction of -17.8 ± 7.3 mmHg over 12 weeks, but this single small trial was later judged at high risk of bias and excluded from the Cochrane pooled analysis.

🟠 Limited quality Mixed funding Effect size: Within-group SBP -17.8 ± 7.3 mmHg (60 mg twice daily, 12 weeks)

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Cautious

not generally recognized as safe and effective for the referenced uses and therefore are considered "new drugs" source↗

L4b EU EFSA

Against

a cause and effect relationship has not been established between the consumption of coenzyme Q10 and the claimed effects source↗

L4c UK NHS

Cautious

Advise people with migraine that the food supplement riboflavin (400 mg once a day) may be effective in reducing migraine frequency and intensity for some people. source↗

L4d TW TFDA / 衛福部

Cautious

訂定「食品原料輔酵素Q10 (Coenzyme Q10)之使用限制及標示規定」 source↗

L5b Mayo Clinic

Cautious

Although findings are mixed, CoQ10 might help lower blood pressure. source↗

L5c Cleveland Clinic

Cautious

CoQ10 can lower blood pressure, so it may not be appropriate to take it if you're on blood pressure medication that also drives those numbers down. source↗

L5e Specialty Society (condition-mapped)

Cautious

CoQ10 may interact with blood pressure medications and the blood thinner warfarin. However, the benefits of CoQ10 are not clear, and more research is needed. source↗

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬5 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-hypertension-INT-coenzyme-q10-001 繁體中文版 →